Methylphenidate for Treating Children With ADHD and Tourette Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00441649
Recruitment Status : Completed
First Posted : March 1, 2007
Last Update Posted : October 31, 2013
National Institute of Mental Health (NIMH)
Information provided by:
Stony Brook University

Brief Summary:
This study will evaluate the safety and effectiveness of methylphenidate in treating attention deficit hyperactivity disorder in children with both attention deficit hyperactivity disorder and Tourette syndrome.

Condition or disease Intervention/treatment Phase
Attention Deficit Disorder With Hyperactivity Tourette Syndrome Drug: Methylphenidate Not Applicable

Detailed Description:

Tourette syndrome is a neurological disorder that is characterized by repetitive, involuntary movements and vocalizations called tics. Many children with Tourette syndrome also have attention deficit hyperactivity disorder (ADHD), which is one of the most common childhood mental disorders. Symptoms of ADHD usually include impulsiveness, inattention, and hyperactivity. ADHD is commonly treated with a stimulant medication, such as methylphenidate. It is under debate, however, whether using stimulants in children with Tourette syndrome exacerbates tics associated with the disorder. This study will evaluate the safety and effectiveness of methylphenidate in treating ADHD in children who have both ADHD and Tourette syndrome.

Participants in this 6-week, double blind study will receive three doses of methylphenidate over the course of the study. Each dose will be taken twice daily, approximately 3.5 hours apart, for 2 weeks. Medication will be dispensed at study visits, which will occur once every 2 weeks. At each study visit, participants will take a dose of the medication. About an hour after ingesting the medication, they will be observed in a classroom setting by study physicians. Participants will then complete a Continuous Performance Test, which will measure their voluntary attention levels. The following will be assessed at study visits: ADHD symptoms; oppositional and aggressive behavior; frequency and severity of tics and obsessive compulsive disorder symptoms; rebound tic exacerbation; effects of methylphenidate on tic-related problems with self-esteem, family life, academic and social performance, and overall tic severity; anxiety and mood symptoms; and adverse drug reactions. Parents and teachers will also complete assessments of participants' behavior on 2 days of each week for the duration of the study.

Study Type : Interventional  (Clinical Trial)
Enrollment : 71 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Methylphenidate Treatment of ADHD in Children With Tourette Syndrome
Study Start Date : February 2000
Actual Primary Completion Date : June 2004
Actual Study Completion Date : January 2007

Primary Outcome Measures :
  1. ADHD symptoms
  2. Oppositional and aggressive behavior
  3. Frequency and severity of tics and obsessive compulsive disorder symptoms
  4. Tic impairment, tic severity, and clinical response
  5. Anxiety and mood symptoms
  6. Rebound tic exacerbation
  7. Adverse drug reactions (all measured at 2-week intervals throughout the study)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   6 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of ADHD or ADHD plus Tourette syndrome

Exclusion Criteria:

  • Determined to be dangerous to self or others
  • Scores less than 70 on an IQ test
  • Any seizure disorder, major organic brain dysfunction, major medical illness, major mood disorder, psychosis, pervasive developmental disorder, or peripheral sensory loss
  • Any condition that may make use of methylphenidate unsafe

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00441649

Sponsors and Collaborators
Stony Brook University
National Institute of Mental Health (NIMH)
Principal Investigator: Kenneth D. Gadow, PhD State University of New York at Stony Brook

Publications: Identifier: NCT00441649     History of Changes
Other Study ID Numbers: R01MH045358 ( U.S. NIH Grant/Contract )
R01MH045358 ( U.S. NIH Grant/Contract )
First Posted: March 1, 2007    Key Record Dates
Last Update Posted: October 31, 2013
Last Verified: October 2013

Keywords provided by Stony Brook University:

Additional relevant MeSH terms:
Tourette Syndrome
Attention Deficit Disorder with Hyperactivity
Pathologic Processes
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tic Disorders
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Central Nervous System Stimulants
Physiological Effects of Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents